The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Link
http://www.nature.com/articles/s41388-018-0553-0.pdf
Reference60 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA J Clin. 2017;67:7–30.
2. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer. 1987;60:2284–303.
3. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, et al. Clinical cancer advances 2011: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012;30:88–109.
4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.
5. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dissecting SOX2 expression and function reveals an association with multiple signaling pathways during embryonic development and in cancer progression;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09
2. Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors;Cell Reports Medicine;2024-08
3. Obg-like ATPase 1 exacerbated gemcitabine drug resistance of pancreatic cancer;iScience;2024-06
4. Cordycepin Enhanced Therapeutic Potential of Gemcitabine against Cholangiocarcinoma via Downregulating Cancer Stem-Like Properties;Biomolecules & Therapeutics;2024-04-09
5. Conquering chemoresistance in pancreatic cancer: Exploring novel drug therapies and delivery approaches amidst desmoplasia and hypoxia;Cancer Letters;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3